Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.

about

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.

Item

http://www.wikidata.org/entity/Q38787278

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Update on optimal treatment fo ...... ITG expert meeting: ECCO 2015.

@en

type

Item

label

Update on optimal treatment fo ...... ITG expert meeting: ECCO 2015.

@en

prefLabel

Update on optimal treatment fo ...... ITG expert meeting: ECCO 2015.

@en

P1476

Update on optimal treatment fo ...... ITG expert meeting: ECCO 2015.

@en

P2093

Cornelis Ja Punt

http://www.w3.org/2001/XMLSchema#string

Daniel G Haller

http://www.w3.org/2001/XMLSchema#string

Eva Segelov

http://www.w3.org/2001/XMLSchema#string

Jeremy D Shapiro

http://www.w3.org/2001/XMLSchema#string

Matthew Burge

http://www.w3.org/2001/XMLSchema#string

Niall C Tebbutt

http://www.w3.org/2001/XMLSchema#string

Nick Pavlakis

http://www.w3.org/2001/XMLSchema#string

Peter Gibbs

http://www.w3.org/2001/XMLSchema#string

Subotheni Thavaneswaran

http://www.w3.org/2001/XMLSchema#string

Timothy J Price

http://www.w3.org/2001/XMLSchema#string

P2860

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

P304

557-571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2016.1170594

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Arnold

Christos S Karapetis

P577

2016-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27010906

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer